The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Increased NADP reduced (NADPH) oxidase 4 (Nox4) and reduced expression of the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) contribute to hypoxia-induced pulmonary hypertension (PH). To examine the role of Nox4 activity in pulmonary vascular cell proliferation and PH, the current study used a novel Nox4 inhibitor, GKT137831, in hypoxia-exposed human pulmonary artery endothelial or smooth muscle cells (HPAECs or HPASMCs) in vitro and in hypoxia-treated mice in vivo. HPAECs or HPASMCs were exposed to normoxia or hypoxia (1% O(2)) for 72 hours with or without GKT137831. Cell proliferation and Nox4, PPARγ, and transforming growth factor (TGF)β1 expression were measured. C57Bl/6 mice were exposed to normoxia or hypoxia (10% O(2)) for 3 weeks with or without GKT137831 treatment during the final 10 days of exposure. Lung PPARγ and TGF-β1 expression, right ventricular hypertrophy (RVH), right ventricular systolic pressure (RVSP), and pulmonary vascular remodeling were measured. GKT137831 attenuated hypoxia-induced H(2)O(2) release, proliferation, and TGF-β1 expression and blunted reductions in PPARγ in HPAECs and HPASMCs in vitro. In vivo GKT137831 inhibited hypoxia-induced increases in TGF-β1 and reductions in PPARγ expression and attenuated RVH and pulmonary artery wall thickness but not increases in RVSP or muscularization of small arterioles. This study shows that Nox4 plays a critical role in modulating proliferative responses of pulmonary vascular wall cells. Targeting Nox4 with GKT137831 provides a novel strategy to attenuate hypoxia-induced alterations in pulmonary vascular wall cells that contribute to vascular remodeling and RVH, key features involved in PH pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, so far no direct antioxidative side effects of GKT 137831 were reported [392] highlighting this substance as the most promising inhibitor for Nox enzymes not only in vitro but also in vivo [94,409,411,412,413,414].”
From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [413]
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989 · cited 6×
“NADPH oxidases catalyze the reduction of molecular oxygen to generate superoxide (O2 ), hydrogen peroxide (H2O2), or secondary oxidants (7).”
BackgroundInfluentialHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Nihon-Kokyuki-Gakkai (2011) · Cited by 1,301
Vascular NAD(P)H oxidases: specific features, expression, and regulation
Lassègue, B., & Clempus, R. E. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00758.2002 · Cited by 1,032 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundGriendling, K. K., Sorescu, D., Lassègue, B., & Ushio-Fukai, M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2175 · Cited by 955 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundSuperoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847 · cited 5×
“As the predominant Nox isoform expressed in VSMCs and ECs, Nox4 constitutes an attractive target for PH therapy.”
BackgroundInfluentialNox proteins in signal transduction
Brown, D. I., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 832 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundCucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundApocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100214 · Cited by 735 · cited 1×
“Apocynin also functions as an antioxidant in vascular ECs and SMCs, cells that lack the myeloperoxidase activity necessary for apocynin activation (37).”
Background
Cited by
Items 101–145 of 145
Xie, X., Li, S., Zhu, Y., Liu, L., Pan, Y., Wang, J., Shi, W., Song, Y., Yang, L., Gao, L., et al. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2625-9 · Cited by 22
“Recent studies have further indicated that a reduction of PPARγ expression has been observed in the vascular lesions of patients with PH and several experimental models of PH (Ameshima et al. 2003; Bijli et al. 2015; Green et al. 2012; Kang et al. 2013; Kim et al. 2010a; Lu et al. 2013).”
BackgroundYuan, T., Chen, Y., Zhang, H., Fang, L., & Du, G. (2017) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x17500653 · Cited by 23
Oxidation of PKGIα mediates an endogenous adaptation to pulmonary hypertension
Rudyk, O., Rowan, A., Prysyazhna, O. D., Krasemann, S., Hartmann, K., Zhang, M., Shah, A. M., Ruppert, C., Weiß, A., SCHERMULY, R. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904064116 · Cited by 22
“A large body of literature describes detrimental effects of Nox4 in PH (21, 22, 41, 42).”
Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Chan, E. C., Liu, G., & Dusting, G. J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666151029111127 · Cited by 22
Datla, S. R., Hilenski, L. L., Seidel-Rogol, B. L., Dikalova, A., Harousseau, M. E., Punkova, L., Joseph, G., Taylor, W. R., Lassegue, B. P., & Griendling, K. K. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0103-y · Cited by 18
Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology
Alruwaili, N., Kandhi, S., Sun, D., & Wolin, M. S. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7657 · Cited by 18
“Inhibition of Nox4 with GKT137831or a plant-derived pigment plumbagin has been shown to attenuate hypoxia-induced PH in mice (34, 54).”
BackgroundReyes-Martínez, C., Nguyen, Q. M., Kassan, M., & González, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00803 · Cited by 17
“The effectiveness of GKT 137831 has been demonstrated in cells of the pulmonary vascular wall and cardiac fibroblasts, where it blocks the action of NOX-4 and, thereby, prevents an increase in ROS production (Green et al., 2012).”
InfluentialBijli, K. M., Kang, B., Sutliff, R. L., & Hart, C. M. (2016) · Pulmonary Circulation · doi:10.1086/686012 · Cited by 16
“For example, PPARγ expression is reduced in the lungs of rodents with hypoxiainduced PH,(2,3) in the vascular lesions of patients with idiopathic pulmonary arterial hypertension (IPAH), in the lungs of rats with severe PH,(4) and in pulmonary artery endothelial cells isolated from IPAH patients.(5) Furthermore, target…”
BackgroundSelf-citationYang, J., Li, J., Wang, Q., Xing, Y., Tan, Z., & Kang, Q. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3612 · Cited by 22
NADPH Oxidases: Progress and Opportunities
Martín, A. S., & Griendling, K. K. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5947 · Cited by 16
“Similarly, both Nox2 and Nox4 have been implicated in hypoxia-induced pulmonary hypertension (2, 8).”
Li, S., Lyu, Q., Shi, Q., Bai, Y., Ren, X., & Ma, J. (2024) · Clinical Science · doi:10.1042/cs20231508 · Cited by 15
Adesina, S. E., Wade, B. E., Bijli, K. M., Kang, B., Williams, C. R., Ma, J., Go, Y., Hart, C. M., & Sutliff, R. L. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00258.2016 · Cited by 15
“Nox4 expression is increased in pulmonary artery endothelial cells isolated from patients with idiopathic pulmonary arterial hypertension (IPAH) and in pulmonary and vascular tissue from hypoxia-induced PH models (1, 13, 27, 34, 38).”
BackgroundMethodSelf-citationXi, L., Ruan, L., Yao, X., Zhang, D., Yuan, H., Li, Q., & Yan, C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9309 · Cited by 16
Wang, R., Pan, J., Han, J., Gong, M., Liu, L., Zhang, Y., Liu, Y., Wang, D., Tang, Q., Wu, N., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.790921 · Cited by 15
Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension
Rudyk, O., & Aaronson, P. I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_13 · Cited by 14
Carrillo-Sepúlveda, M. A., Keen, H. L., Davis, D. R., Grobe, J. L., & Sigmund, C. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103786 · Cited by 13
“After 72h, once VSMCs migrated from the edges of the explants, the mesenteric arteries were removed and discarded.”
BackgroundKe, R., Xie, X., Li, S., Pan, Y., Wang, J., Yan, X., Zang, W., Gao, L., & Li, M. (2017) · Oncotarget · doi:10.18632/oncotarget.20582 · Cited by 12
“Recent studies have further indicated that PPAR γ expression is reduced in pulmonary vascular lesions of PH patients and several PH experimental models [8, 26, 27].”
BackgroundNADPH oxidase 4 expression in the normal endometrium and in endometrial cancer
Degasper, C., Brunner, A., Sampson, N., Tsibulak, I., Wieser, V. E., Welponer, H., Marth, C., Fiegl, H., & Zeimet, A. G. (2019) · Tumor Biology · doi:10.1177/1010428319830002 · Cited by 12
Bouchet, C., Cardouat, G., Douard, M., Coste, F., Robillard, P., Delcambre, F., Ducret, T., Quignard, J., Vacher, P., Baudrimont, I., et al. (2022) · Cells · doi:10.3390/cells11182795 · Cited by 14
Jasińska-Stroschein, M., & Orszulak–Michalak, D. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.04.001 · Cited by 13
Beneficial effects of fenofibrate in pulmonary hypertension in rats
Galhotra, P., Prabhakar, P., Meghwani, H., Mohammed, S. A., Banerjee, S., Seth, S., Hote, M. P., Reeta, K. H., Ray, R., & Maulik, S. K. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3355-3 · Cited by 10
Murugesan, P., Zhang, Y., Youn, J. Y., & Cai, H. “. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102348 · Cited by 10
“hypoxia induced development of PH [45,46].”
NADP+/NADPH in Metabolism and its Relation to Cardiovascular Pathologies
Sun, Y., Wu, D., & Hu, Q. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673275187231121054541 · Cited by 8
Ning, H., Deng, J., Chen, F., Liu, Y., Kong, D., Shan, L., Zhang, Z., & Hu, T. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105791 · Cited by 9
Lycopene Ameliorates Hypoxic Pulmonary Hypertension via Suppression of Oxidative Stress
Wang, D., Ji, Y., Wang, R., Cheng, K., Liu, L., Wu, N., Tang, Q., Zheng, X., Li, J., Zhu, Z., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9179427 · Cited by 8
“Moreover, NOX4 is con fi rmed to elevate pulmonary vascular remodeling in the HPH rodent models [51, 52].”
Miao, Y., Dong, Y., Huang, P., Zhao, X., Huang, Z., Yao, J., He, L. N., & Xu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.18908 · Cited by 9
“GKT137831 is a novel and specific dual Nox1/ Nox4 inhibitor [23, 24].”
BackgroundKim, J., Kim, J.-W., Lim, H. J., Lee, S., Bae, Y. S., & Kim, J. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10303-x · Cited by 6
Isoform-Selective Nox Inhibitors: Advances and Future Perspectives
Dustin, C. M., Cifuentes-Pagano, E., & Pagano, P. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-23752-2_21 · Cited by 6
Абатуров, А. Е., Волосовец, А. П., & Borysovа, T. P. (2018) · CHILD`S HEALTH · doi:10.22141/2224-0551.13.2.2018.129558 · Cited by 4
Kim, H. J., Yoo, H. Y., Lin, H. Y., Oh, G. T., Zhang, Y. H., & Kim, S. J. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00061.2016 · Cited by 3
Role of ROS and ROS generating enzymes in the human ovary
Buck, T. (2018) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.22901 · Cited by 4
Wang, Y., Ben, T., Fang, J., Li, Z., Ding, J., Xu, L., Lin, K., & Jiang, L. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.10941 · Cited by 2
“The consistent identification of NOX4 as a pathological effector positions it as a highly attractive therapeutic target for PH. Specific small-molecule inhibitors of NOX4, such as setanaxib, have been rigorously tested in preclinical PH models [173].”
Itani, H. A., Dikalov, S., & Harrison, D. G. (2013) · Circulation · doi:10.1161/circulationaha.113.002564 · Cited by 2
Advances and Strategies in NADPH Oxidase Inhibitors and Activators Patents
Page, P. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.31 · Cited by 2
Self-citationMurugesan, P., Zhang, Y., Zhang, Y., Youn, J. Y., & Cai, H. “. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103710 · Cited by 1
“Of note, activation of NOX4 has been implicated in the development of PH in hypoxia exposed mice [38,39], and that scavenging of ROS is effective in attenuating PH in hypoxia induced PH model [40,41].”
Xiaotong, G., Yuchun, F., Ting, J., Xia, C., Haifeng, J., Chen, J., & Xin, H. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70218 · Cited by 1
“The study by Green DE et al. [21] showed that chronic hypoxia leads to vascular remodeling in small pulmonary vessels (less than 100 μm) in mice, with thickening of the vessel walls and an increase in the number of α- SMA-positive vessels.”
Redox Signaling and Persistent Pulmonary Hypertension of the Newborn
Sharma, M., & Afolayan, A. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63245-2_16 · Cited by 1
Nox4: From Discovery to Pathophysiology
Hecker, L., Kato, K., & Griendling, K. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-23752-2_12 · Cited by 3
Reactive Oxygen Species and Antioxidants in Pulmonary Hypertension and Right Heart Failure
Pavlickova, L., Zungu-Edmondson, M., & Suzuki, Y. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_123
Oxidative Stress and the Perinatal Circulation
Steinhorn, R. H., & Wedgwood, S. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-1405-0_10
Oosterheert, W. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/505
Aliakbarian, M., Ashrafzadeh, K., Ferns, G. A., Hadian, R., Khodashahi, R., & Arjmand, M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673356252250213105931 · Cited by 1
ROS-Mediated Cellular Signaling Pathways in Metabolic Disorders
Gunasekaran, S. K., Gobinath, M., Roychowdhury, P., Maideen, N. M. P., & Kuppusamy, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-11752-6_4
NADPH Oxidases and Pulmonary Fibrosis
Deskin, B., & Thannickal, V. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-21135-4_22
Moreno-Caceres, S., & Marciano, D. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209096
“The experimental model is a sixth since inhibitor studies in chronic hypoxia and in SU5416/hypoxia have produced different patterns of pulmonary vascular and right ventricular benefit [11,14].”
Metadata
- Authors
- Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M.
- Affiliations
- Emory University (US)
- Genkyotex (Switzerland) (CH)
- Corresponding author
- Hart, C. Michael
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-01
- Volume
- 47
- Issue
- 5
- Pages
- 718-726
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC3547100
- OpenAlex
- W1990038383
- Cited by
- 146
- References
- 50
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 14 · 2018: 18 · 2017: 19 · 2016: 16 · 2015: 11 · 2014: 14 · 2013: 13
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (NHLBI T32, HL081064, HL 60917)
- National Heart, Lung, and Blood Institute (HL-60917, HL-081064, T32HL076118, P01HL081064, R01HL102167, R01HL060917)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074518)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- NOX4, GKT137831, NADPH oxidase inhibitors, hypoxia, pulmonary hypertension, PPARγ, TGF-β1, pulmonary artery endothelial cells, pulmonary artery smooth muscle cells, right ventricular hypertrophy, pulmonary vascular remodeling, hydrogen peroxide
- MeSH terms
- NADPH Oxidase 4, Rosiglitazone, Animals, Cells, Cultured, Endothelium, Vascular, Humans, Hydrogen Peroxide, Hypertension, Pulmonary, Lung, Mice, Inbred C57BL, Pulmonary Artery, Pyrazoles, Pyridines, Pyridones, Cell Hypoxia, Gene Expression, Proliferating Cell Nuclear Antigen, NADPH Oxidases, Ventricular Remodeling, Myocytes, Smooth Muscle, RNA Interference, Endothelial Cells, Thiazolidinediones, Pyrazolones, PPAR gamma, Cell Proliferation, Mice, Transforming Growth Factor beta1, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.